These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 320504)

  • 1. [Depletive treatment of uncompensated liver cirrhosis with high doses of spirolactone only].
    Zotti S; Dagnini G; Abrahamsohn C; de Nadai Frank A; Sandri R
    Minerva Med; 1977 Feb; 68(7):431-7. PubMed ID: 320504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High doses of spironolactone (Aldactone, SC-14266, Verospirone) alone and in combination with triamterene and-or diuretics in the treatment of refractory edema associated with secondary hyperaldosteronism.
    Radó JP; Marosi J; Takó J
    Endokrinologie; 1970; 57(1):46-62. PubMed ID: 4923990
    [No Abstract]   [Full Text] [Related]  

  • 3. Reversal of the suppressed potassium excretion during treatment with combinations of antikaliuretic drugs (spironolactone, canrenone, triamterene, amiloride) in patients with liver cirrhosis.
    Radó JP; Sawinsky I; Juhos E
    Int J Clin Pharmacol Biopharm; 1976 Oct; 14(3):163-7. PubMed ID: 1002353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of cirrhotic edemas with triamterene, amiloride and spirolactone. New clinical and biological facts].
    Vesin P
    Schweiz Med Wochenschr; 1971 Mar; 101(11):398-401. PubMed ID: 5558553
    [No Abstract]   [Full Text] [Related]  

  • 5. The urinary sodium: potassium ratio and response to diuretics in resistant oedema.
    Alexander WD; Branch RA; Levine DF; Hartog M
    Postgrad Med J; 1977 Mar; 53(617):117-21. PubMed ID: 323834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist?
    Bansal S; Lindenfeld J; Schrier RW
    Circ Heart Fail; 2009 Jul; 2(4):370-6. PubMed ID: 19808361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors predicting hyperkalemia in patients with cirrhosis receiving spironolactone.
    Abbas Z; Mumtaz K; Salam A; Jafri W
    J Coll Physicians Surg Pak; 2003 Jul; 13(7):382-4. PubMed ID: 12887837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal effects of treatment with diuretics, octreotide or both, in non-azotemic cirrhotic patients with ascites.
    Kalambokis G; Economou M; Fotopoulos A; Bokharhii JA; Katsaraki A; Tsianos EV
    Nephrol Dial Transplant; 2005 Aug; 20(8):1623-9. PubMed ID: 15886218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of deranged sodium and water homeostasis in decompensated cirrhosis.
    Epstein M; Pins DS; Schneider N; Levinson R
    J Lab Clin Med; 1976 May; 87(5):822-39. PubMed ID: 1270890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative pharmacodynamics of furosemide and muzolimine in cirrhosis. Study on renal sodium and potassium handling and renin-aldosterone axis.
    Bernardi M; De Palma R; Trevisani F; Santini C; Servadei D; Gasbarrini G
    Z Kardiol; 1985; 74 Suppl 2():129-34. PubMed ID: 3890391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spironolactone diuresis in patients with cirrhosis and ascites.
    Eggert RC
    Br Med J; 1970 Nov; 4(5732):401-3. PubMed ID: 5481518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of azosemide and furosemide in ascitic patients without and during administration of spironolactone.
    Radó JP; Molnár Z; Hartai A; Gercsák G
    Int J Clin Pharmacol Ther Toxicol; 1982 Nov; 20(11):532-7. PubMed ID: 7174156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Controlled study of the effect of long-term administration of canrenoate potassium in cirrhotic ascites].
    Traina M; Vizzini GB
    Minerva Med; 1986 Jan; 77(3-4):87-91. PubMed ID: 3511409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of aldactone on potassium storage in patients with ascitic cirrhosis].
    Lévy VG; Lassale B; Del Corso A; Caroli J
    Ann Med Interne (Paris); 1970 Feb; 121(2):183-90. PubMed ID: 5491199
    [No Abstract]   [Full Text] [Related]  

  • 16. [Correlations between blood pressure, blood volume and plasma renin during therapy with diuretics in essential hypertension. Comparison between the mineralocorticoid antagonist spironolactone and the "loop" diuretic mefruside].
    Beretta-Piccoli C; Weidmann P; de Châtel R; Hirsch D; Reubi FC
    Schweiz Med Wochenschr; 1977 Jan; 107(4):104-15. PubMed ID: 834983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spironolactone and frusemide in cirrhosis with ascites.
    Sadikali F
    Br J Clin Pract; 1973 Jun; 27(6):222-4. PubMed ID: 4582147
    [No Abstract]   [Full Text] [Related]  

  • 18. [The behavior of uricemia during treatment with spironolactone and with other diuretics].
    Bufalari A; Meloni G
    Minerva Med; 1967 Nov; 58(89):3815-22. PubMed ID: 6074933
    [No Abstract]   [Full Text] [Related]  

  • 19. Attenuation by spironolactone of the magnesiuric effect of acute frusemide administration in patients with liver cirrhosis and ascites.
    Stergiou GS; Mayopoulou-Symvoulidou D; Mountokalakis TD
    Miner Electrolyte Metab; 1993; 19(2):86-90. PubMed ID: 8377729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Study of the new diuretic: Amiloride (MK-870)].
    Jenny M
    Praxis; 1969 Sep; 58(38):1192-6. PubMed ID: 5395178
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.